Joshua Longbottom and colleagues 1 highlight once again that snake envenoming is a major health issue affecting remote and rural regions of the tropics. They use information about venomous snake distribution, health-care access, and availability of antivenom to identify the most vulnerable populations to snakebite. This modelling study 1 reported in The Lancet identified about 92·66 million people living in regions vulnerable to snakebite, including sub-Saharan Africa, southeast Asia, and Indonesia. The major limitation of Longbottom and colleagues' study 1 is that they do not report actual snakebites-making a number of assumptions, such as different venomous snakes and different human populations living together. This assumption results in the same risk of snake envenoming across different geographical regions, which is unlikely to be true. They also used a Nigerian retrospective observational study, 2 with more than 90% of bites from Echis ocellatus (sawscaled viper), in which deaths are due to coagulopathy and bleeding, to estimate the effect of delay to antivenom on mortality. The effectiveness of antivenom is highly species specific and different for neurotoxic envenoming, 3 and cannot be administered early enough to prevent early prehospital deaths from cardiac arrest. 4 Reassuringly, Longbottom and colleagues identified the same geographical regions as did a previously published global study of snakebites, which reported between 421 000 and 1 841 000 additional envenomings occurring annually, and 20 000-94 000 deaths. 5 15 years ago, Lalloo and colleagues 6 called for the global health community's attention to the problem of snake envenoming in Africa, highlighting the high cost and paucity of antivenom and the socioeconomic burden of snake envenoming. They stated the urgent need for research on the burden and economic effect of snake envenoming, and the need to improve antivenom development and supply to Africa.
What progress has been made since then? In 2017, WHO categorised snakebite as a high-priority neglected tropical disease, and in May, 2018, WHO resolved to decrease the morbidity and mortality of snake envenoming, and "coordinate global efforts to control snakebite".
Although acute effects of snakebites are relatively well understood, morbidity and cost associated with long-term effects are poorly studied globally. Many snakebite survivors, once treated for acute illness, are never followed up. Recent research has provided good evidence for the psychological and economic burden of snakebite. 7 For example, patients with snakebites in Sri Lanka have symptoms of depression and posttraumatic stress disorder, and 10% did not return to work, 7 which is a substantial economic burden to the country.
Antivenom was first developed in the 1890s, along with the tetanus vaccine. Vaccines have been one of the greatest successes in public health, resulting in the eradication of some diseases and substantial reductions in morbidity and mortality. 8 By contrast, there is a crisis in antivenom supply, and technology not dissimilar from early vaccines is still used to manufacture antivenom. 9 Human monoclonal antibodies are the future for cancer treatment, 10 but poorly purified equine polyclonal antibodies to treat snake envenoming still exists with high rates of adverse reactions.
11
There continues to be a paucity of evidence to support antivenom effectiveness for snake envenoming. This doesn't mean antivenoms are ineffective as they bind to snake toxins in vitro. 12, 13 However, research must provide scientific and clinical trial evidence that antivenoms are clinically effective, because they can cause anaphylaxis and are expensive. More importantly, there is a need to identify for which snakes, what types of toxin effects, and what period of time antivenom will be effective.
It is clear that the earlier antivenom is administered, the more effective it is in preventing toxin effects and potentially reversing some effects. 2, 3 To make early administration possible, there must be immediate access to antivenom, requiring increased production, and bedside diagnostic testing to identify envenomed patients. With training and standardisation, whole blood clotting testing appears to identify coagulopathy in 80% of viper-envenomed patients.
14 Simpler tests with greater diagnostic accuracy, which can also identify all forms of envenoming (eg, neurotoxicity), are required. Testing for common snake enzyme activity is one potential way forward, and the almost ubiquitous group of snake toxins, phospholipase A 2 , might prove useful. 15 15 years on and progress is being made to improve the treatment of snake envenoming. As the Longbottom and colleagues' study confirms, there is a clearer picture of the most vulnerable regions and the overall social and economic burden. Going forward, there is a need to increase research efforts and funding into improved, safer, and more universally available antivenoms. Finally, research must also now focus on prevention of snakebite, a neglected aspect of decreasing snakebite burden.
